Ionis Pharmaceuticals(NASDAQ) IONS

Ionis Pharmaceuticals, Inc. treats serious genetic diseases. These medicines help people with rare muscle and nerve conditions. The company targets genetic instructions in cells to stop disease.

What Does Ionis Sell?

• Neuromuscular Medicines: SPINRAZA treats spinal muscular atrophy, which is a disease that weakens muscles; partner Biogen commercializes this therapy worldwide.
• Metabolic Therapies: TRYNGOLZA reduces fats in the blood for adults with severe hypertriglyceridemia, which is excessively high fat levels; the company independently launched this medicine in June 2026.
• Hereditary Prophylaxis: DAWNZERA prevents swelling attacks caused by hereditary angioedema; the firm independently launched this treatment in the U.S. in August 2025.
• Nerve Condition Treatments: WAINUA treats nerve damage caused by a rare genetic condition; the company co-developed this therapy with AstraZeneca.

Where Is the Company Growing?

• Launched TRYNGOLZA in the U.S. market following approval from the Food and Drug Administration (FDA) in June 2026.
• Licensed commercialization rights for DAWNZERA in Europe and the Asia-Pacific region to Otsuka Pharmaceutical Co., Ltd.
• Advanced zilganersen for Alexander disease toward a Prescription Drug User Fee Act (PDUFA) regulatory deadline of Sept. 22, 2026.
• Earned a $280 million upfront payment from Ono Pharmaceutical Co., Ltd. for the global license of sapablursen in the second quarter of 2025.

Innovation and Global Partnerships

Ionis utilizes proprietary technology to develop medicines that target the genetic source of serious diseases. It leverages a broad network of pharmaceutical partners, including Biogen, AstraZeneca, and Novartis, to manage global distribution and research costs.

Financial Performance Highlights

• Market capitalization reached $13.1 billion in Q2 2026, up 108.6% year over year.
• Commercial revenue increased 27% during the six-month period ended June 30, 2026.
• Total net product sales reached $74.1 million in the first half of 2026.
• Basic net loss was $1.25 per share for the six-month period ended June 30, 2026.
• Total revenue was $514 million for the six-month period ended June 30, 2026.

Bottom Line

Ionis has evolved into a commercial-stage biotechnology company by launching independent products while maintaining a robust partner pipeline. This transition from a research focus to active sales marks a significant shift in its business model.